Navion Neurosciences closes USD 10.8 million seed round led by Angelini Lumira Biosciences Fund

• Navion Neurosciences closed a USD 10.8 million first closing of a seed round led by the Angelini Lumira Biosciences Fund.
• Navion is a preclinical biotech developing precision sodium-channel medicines for genetic epilepsy and chronic neuropathic pain.
• Funding supports lead program advancement, expansion of its AI-enabled NaViGATion discovery platform, structural biology, and human disease biology work.
• Strategy targets pathological neuronal hyperexcitability to improve the therapeutic window versus broader sodium-channel modulation approaches.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lumira Capital Investment Management Inc published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.